A near-infrared dual-locked fluorescent nanoprobe HCy-M@MSN@PEG was developed that can be sequentially activated by glutathione (GSH) and β-galactosidase (β-Gal), enabling highly specific imaging of liver tumors, providing a promising tool for precise liver cancer diagnosis and intraoperative navigation.
Abstract
Accurate intraoperative navigation for solid tumors is often hindered by the nonspecific activation of imaging probes in non-target tissues. In this work, a near-infrared dual-locked fluorescent nanoprobe HCy-M@MSN@PEG was developed that can be sequentially activated by glutathione (GSH) and β-galactosidase (β-Gal), enabling highly specific imaging of liver tumors. This nanoprobe is constructed by encapsulating a β-Gal-responsive small-molecule probe (HCy-M) within PEGylated mesoporous silica nanoparticles (MSN@PEG). Upon exposure to the first biomarker GSH, the nanoprobe undergoes rapid disassembly, releasing the encapsulated HCy-M, which then responds to the second biomarker β-Gal, producing a fluorescence turn-on signal that enables selective imaging of liver tumors. Through meticulous material optimization, including the incorporation of disulfide bonds into both the MSNs framework and surface PEG chains to accelerate GSH responsiveness, as well as the modification of the structure of small-molecule probe to balance loading efficiency and release rate, the nanoprobe achieved a release efficiency of 42.9% within 3 h under GSH stimulation, and the released HCy-M responded to β-Gal within 20 min with a 10.25-fold fluorescence enhancement. The probe efficiently discriminated between normal, senescent, and liver cancer cells. In vivo, it exhibited excellent tumor targeting with a signal-to-background ratio of 4.47 and successfully guided precise resection of liver tumors via fluorescence imaging in mouse models. This work provides a promising tool for precise liver cancer diagnosis and intraoperative navigation, with potential for advancing fluorescence-based theranostics.
Simultaneous visualization of multiple biomarkers offers a more comprehensive view of cancer-associated molecular alterations, yet achieving high sensitivity and spatiotemporal control in complex biological environments remains challenging. To address this, we designed two functionalized tetrahedral DNA nanostructures...
Yun Qiu, Ya-Zhi Wang, Fei-Bing Huang et al.· Talanta: The International J...· 0 citations
It is demonstrated that biotin modification enhances both tumor accumulation and retention, enabling sensitive, long-lasting NTR imaging and offers a reliable tool for real-time NTR monitoring with clear advantages in sensitivity, selectivity, and translational feasibility.
Chang Xu, Ming-Xia Li, Chen-Yu Wang et al.· Analytical Chemistry· 0 citations
Achieving highly sensitive and precise detection and imaging of cancer cells within the body is crucial for providing pathological information support in disease diagnosis and treatment. However, due to the existence of factors such as non-specific activation in local areas, membrane barriers, and the complexity of t...
Li Tang, Ying-Ying Lv, Lin Xu et al.· Analytical Chemistry· 0 citations
Breast cancer is a highly prevalent malignancy, but the conventional single chemotherapy suffers from insufficient therapeutic outcomes. To overcome this challenge, this study developed a dextran-based prodrug nanogel (DDIR) with dual pH/GSH responsiveness to the tumor microenvironment, enabling near-infrared (NIR) flu...
Using a subcutaneous tumor model, it is verified that ONOO−-mediated synergistic phototherapy achieves markedly improved antitumor therapeutic efficacy.
Shu-Di Liu, Qing Hu, Hua-Fei Liu et al.· ACS Applied Nano Materials· 0 citations
A GSH-activated theranostic probe, Np-DOX, which links a sulfonamide-containing naphthalimide derivative with the anti-tumor drug doxorubicin (DOX), represents a promising theranostic platform for monitoring drug delivery while exerting potent anticancer activity.
Le Li, Zhi-Qiang Xu, Ya-Bin Luo et al.· Bioorganic chemistry (Print)· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.